Ben R. Leedle Jr - Nov 19, 2021 Form 4 Insider Report for Diversicare Healthcare Services, Inc. (DVCR)

Role
Director
Signature
/s/ Susan V. Sidwell, Attorney-In-Fact for Ben R. Leedle, Jr.
Stock symbol
DVCR
Transactions as of
Nov 19, 2021
Transactions value $
-$81,285
Form type
4
Date filed
11/22/2021, 07:21 AM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DVCR Common Stock Disposed to Issuer -$81.3K -8.05K -100% $10.10 0 Nov 19, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DVCR Option to purchase Common Stock Disposed to Issuer -15K -100% 0 Nov 19, 2021 Common Stock 15K $8.14 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Ben R. Leedle Jr is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposition pursuant to the terms of the Agreement and Plan of Merger dated as of August 26, 2021 by and among DAC Acquisition, LLC, DVCR Acquisition Corporation and Diversicare Healthcare Services, Inc. (the "Merger Agreement"), exempt under Rule 16b-3.
F2 Pursuant to the terms of the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each share of common stock held by the reporting person immediately prior to the Effective Time was cancelled and the reporting person received an amount in cash equal to $10.10 per share of Company Common Stock, taking into account any changes thereto by reason of the merger.
F3 Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase common stock held by the reporting person immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the excess of $10.10 over the exercise price per share of Company Common Stock underlying such option to purchase, multiplied by (ii) the total number of shares of Company Common Stock subject to such option to purchase, taking into account any changes thereto by reason of the merger.